UK doctors urged to use preventative breast cancer drugs

June 25, 2013

Hundreds of thousands of women at high risk of developing breast cancer in Britain should be given drugs which could dramatically reduce their chances of getting the disease, doctors were advised Tuesday.

In guidelines issued by the National Institute for Health and Care Excellence (Nice), up to half-a-million women with a family history of the illness should receive the £120 ($185, 141 euros), five-year course of or raloxifene.

The "one-a-day" programme is an alternative to the surgery chosen by celebrities including and Sharon Osbourne, said Nice.

Tamoxifen was shown in a clinical trial to reduce the risk of developing by about 50 percent in high-risk post-menopausal women.

Another trial found raloxifene reduced the risk by around 38 percent although neither drug is currently licensed as a in Britain.

"Tamoxifen is extremely cost effective, that's because it's extremely cheap... and treating someone with costs many thousands of pounds," explained professor Gareth Evans, who helped to develop the guidelines.

"So this treatment is potentially not just cost-effective but cost saving to the NHS and more importantly for women, they don't have to go through the stress and trauma of a diagnosis, radiotherapy, potentially chemotherapy.

"So it's a major breakthrough for women that they are going to be able to be offered this treatment in the future," he added.

campaigners praised the report.

"We believe that this guideline is a game changer for people with a family history of breast cancer," said Caitlin Palframan, assistant head of policy at Breakthrough Breast Cancer.

"In fact for breast cancer overall it's a historic step for prevention.

"We think more women will have more options to reduce their risk, which ultimately means we will prevent more breast cancer cases."

Around 50,000 women and 400 men develop breast cancer every year in Britain, according to Nice figures.

Explore further: UK considers preventative drugs for breast cancer (Update)

Related Stories

UK considers preventative drugs for breast cancer (Update)

January 15, 2013
Britain's National Health Service may soon offer women at high risk of developing breast cancer drugs normally used to treat the disease as a prevention strategy.

Newly identified markers may predict who will respond to breast cancer prevention therapy

June 13, 2013
Genetic variations, known as single nucleotide polymorphisms (SNPs), in or near the genes ZNF423 and CTSO were associated with breast cancer risk among women who underwent prevention therapy with tamoxifen and raloxifene, ...

Early mammograms in young women at increased breast cancer risk may save lives

June 18, 2013
(Medical Xpress)—Findings, published in journal Familial Cancer, show women under the age of 40 at higher risk of breast cancer who went for mammographic screening had their breast cancer detected at an earlier, more easily ...

Study confirms long term benefits of tamoxifen

June 3, 2013
(Medical Xpress)—Taking tamoxifen for 10 rather than five years halves the risk of women dying from the most common kind of breast cancer, according to new research being presented at this year's ASCO conference.

Rural women less likely to get radiation therapy after lumpectomy for breast cancer

June 24, 2013
Rural women with breast cancer are less likely than their urban counterparts to receive recommended radiation therapy after having a lumpectomy, a breast-sparing surgery that removes only tumors and surrounding tissue, a ...

Mammograms reveal response to common cancer drug

April 22, 2013
Researchers at Karolinska Institutet have developed a method for assessing the effect of tamoxifen, a common drug to prevent the relapse of breast cancer. The key lies in monitoring changes in the proportion of dense tissue, ...

Recommended for you

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Physical activity could combat fatigue, cognitive decline in cancer survivors

July 25, 2017
A new study indicates that cancer patients and survivors have a ready weapon against fatigue and "chemo brain": a brisk walk.

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.